2026年1月26日至30日，政协第十三届山东省委员会第四次会议在济南召开。 在此次会议上，山东省政协委员、海尔集团董事局副主席谭丽霞带来《关于推 进医疗科技成果转化做强全省医养健康产业的建议》。 她在这份提案中提出，建议开放AI+大健康场景，打造国际化前沿科技转化枢纽，构建山东全省成果转化加速体系等举措，加速医疗科技成果转化、做大做 强山东省医疗健康产业。 破解"达尔文之海"的探索 在《2026年山东省政府工作报告》中，山东提出将在2026年壮大人工智能、生物医药、新能源汽车、航空航天与低空经济4个千亿级新兴潜力产业。 在谭丽霞看来，在生物医药领域，山东有着得天独厚的资源优势。山东作为经济与人口大省，坐拥9个国家区域医疗中心和多个国家级创新平台，临床资源 富集，制造业底蕴深厚。 但是，临床发现与前沿的工程研发之间长期存在"海峡"，缺乏高效通达的"航船"与"桥梁"。这一现象被称为医工转化的"达尔文之海"，大量有潜力的技术创 新在转化途中折戟。 因为医疗科技创新有着"基础理论发现—关键技术突破—核心装备研制—工艺工程放大—临床验证注册—产业应用推广"漫长的链条，涉及"医、研、企、 金、服"多个环节，有着周期长、 ...

2026年1月26日至30日，政协第十三届山东省委员会第四次会议在济南召开。 在此次会议上，山东省政 协委员、海尔集团董事局副主席谭丽霞带来《关于推进医疗科技成果转化做强全省医养健康产业的建 议》。 她在这份提案中提出，建议开放AI+大健康场景，打造国际化前沿科技转化枢纽，构建山东全省成果转 化加速体系等举措，加速医疗科技成果转化、做大做强山东省医疗健康产业。 破解"达尔文之海"的探索 在《2026年山东省政府工作报告》中，山东提出将在2026年壮大人工智能、生物医药、新能源汽车、航 空航天与低空经济4个千亿级新兴潜力产业。 在谭丽霞看来，在生物医药领域，山东有着得天独厚的资源优势。山东作为经济与人口大省，坐拥9个 国家区域医疗中心和多个国家级创新平台，临床资源富集，制造业底蕴深厚。 海医汇由海尔大健康产业"盈康一生"牵头，携手中国研究型医院学会、山东产业技术研究院等共同成 立。该平台属于非营利组织，于2024年正式成立，至今汇聚60余家科研高校和医疗机构，包括多位院士 在内的100余位权威专家及1100余名研发人员入驻，以"链接者"与"加速者"的双重身份，通过构建创新 模式、提升转化效率、升级生态系统，为中 ...

Core Insights - The second "Haiyi Hui Medical Technology Innovation Ecosystem Conference" was held in Beijing, focusing on AI and technology's role in advancing healthcare in China by 2030 [1] - The conference aimed to address the low medical achievement conversion rate in China, which has been below 8%, highlighting the need for collaboration across research, clinical validation, and industrial transformation [2][3] Group 1: Medical Innovation and Collaboration - The establishment of Haiyi Hui aims to create a collaborative platform for medical and industrial transformation, linking over 100 research institutions and hospitals to conduct more than 600 distributed clinical trials [2] - The conference emphasized the importance of aligning research with clinical needs to overcome barriers in the medical innovation process [3] - A call for an open and collaborative mechanism was made to break down barriers in data, disciplines, and institutions, ensuring a free flow of innovative resources [2] Group 2: Accelerating Technology Transfer - The conference highlighted the need for a transformation system that integrates enterprises, clinical needs, and deep collaboration between academia and industry to enhance the speed of technology transfer [4] - Haiyi Hui announced over ten groundbreaking technologies in various fields, showcasing a complete cycle from technological breakthroughs to clinical application [5] - The integration of AI in healthcare is seen as a key driver for enhancing service accessibility, precision, and efficiency [6] Group 3: Talent Development and Social Responsibility - Haiyi Hui has initiated a "Science and Technology Elite Cultivation Program" to support young researchers and innovation teams, focusing on rare and difficult diseases [7] - The program aims to build a collaborative training system that connects basic research, clinical practice, and technology transfer [7] - The establishment of the "China Youth Entrepreneurship and Employment Foundation" aims to strengthen the cultivation of composite talents in the healthcare sector [7] Group 4: Strategic Vision and Future Directions - Haiyi Hui is exploring pathways to drive medical industrial transformation through ecological forces and AI integration for high-quality development in the health industry [8] - The platform has established mechanisms for integrating clinical, research, and industrial efforts, as well as channels for technology, capital, and market transformation [9] - The future of medical innovation is viewed as a success of the ecosystem rather than individual technologies, with aspirations to integrate into a larger domestic and international cycle [9]

Core Insights - The event "First Medical Innovation Exchange: Medical Engineering Transformation Salon" was successfully held in Beijing, focusing on the application of energy source technology in dermatology and promoting high-quality development in the medical industry [1][16] Group 1: Medical Engineering Transformation - Medical engineering transformation is identified as a key pathway to bridge the gap between technological innovation and application [3] - The integration of interdisciplinary collaboration is emphasized as the core driving force for medical engineering transformation, with Tsinghua University's Engineering Physics Department leveraging diverse academic strengths for medical technology innovation [3] - The collaboration between YOUMAGIC Shuliti and Weimai Medical has led to the development of various products, including RF skin treatment devices and terahertz biological effect testing systems, creating a closed-loop model for industry innovation [3][11] Group 2: Clinical Applications and Innovations - The core value of medical engineering transformation lies in addressing real clinical pain points, with a focus on RF technology in dermatology [5] - YOUMAGIC's innovative device utilizes a 100-millisecond pulse design to enhance patient comfort while maintaining treatment efficacy, leading to increased market acceptance [5] - Experts from various fields shared practical experiences, highlighting the importance of patient-centered and practical goals in medical engineering integration [7] Group 3: Collaborative Ecosystem - The construction of a medical engineering transformation ecosystem requires deep collaboration among government, industry, academia, and medical sectors [9] - The lack of "translators" who can connect medical pain points with engineering solutions is identified as a core bottleneck in the transformation process [9] - YOUMAGIC and Weimai Medical are committed to fostering interdisciplinary teams and have established a research center with Tsinghua University to facilitate the transition from laboratory to clinical application [11][14] Group 4: Future Directions and Strategic Initiatives - YOUMAGIC plans to expand energy source technology into vascular intervention, dermatology, and immunotherapy, aiming for breakthroughs in high-end medical devices [14] - A strategic cooperation agreement was signed with Shouke Medical Valley to advance technology transformation and industry incubation [14] - The company is launching a "Young Physician Training Program" to cultivate professionals with both engineering and clinical insights, ensuring a continuous supply of innovative talent for the industry [14][16]

Core Insights - China is emerging as a global center for medical device innovation, with an increasing number of Chinese companies appearing in the global medical device TOP 100 rankings and many showing upward trends in their positions [1] - The collaboration between industry, hospitals, and research institutions is identified as the "innovation code" in China's medical device sector, exemplified by the recent approval of a low-temperature plasma device developed by InnoVate and Fudan University [1][2] - The innovation ecosystem is driven by a model of "clinical demand-driven + platform support + full-cycle collaboration," emphasizing the deep integration of clinical needs and engineering [6][7] Industry Developments - The low-temperature plasma product developed for the digestive endoscopy field took eight years to design and optimize, and it has received domestic registration, with plans for registration in Japan and the EU next year [2][3] - Historically, the digestive endoscopy market has been dominated by multinational companies, but the introduction of this new technology aims to disrupt that monopoly [3] - The product's development involved close collaboration with clinical experts, ensuring that clinical experiences were translated into technical parameters [3][6] Company Performance - InnoVate's overseas revenue has reached 55% of total profits, with a projected overall sales growth of around 20% by 2025 [8] - The company has successfully penetrated the global market, with its single-use endoscope solutions accounting for 80% of its overseas revenue [8][9] - The brand's influence has grown, allowing InnoVate to diversify its business and reduce reliance on individual products, with the new plasma device expected to drive future revenue growth [9][10] Innovation and Market Strategy - The shift from imitation to innovation in China's medical device industry is highlighted, with a focus on creating high-quality products that meet clinical needs [9][10] - The establishment of a collaborative research model involving hospitals, universities, and companies has been crucial in addressing clinical challenges and fostering innovation [6][7] - The current phase of the medical device industry in China is characterized as a "strategic leap period," where companies are transitioning from mere manufacturers to influential players in setting international standards [10]

Core Insights - The 2025 Global Healthcare Innovation Summit will be held in Shanghai on November 8, focusing on bridging the gap between clinical needs and industrial applications in the healthcare sector [12][11]. - The summit aims to gather clinical experts from the US, Europe, and China to discuss innovative healthcare solutions and share practical case studies [12][11]. - Key topics will include the transformation of clinical innovations under commercial insurance policies and the development of a collaborative ecosystem for healthcare innovation [12][11]. Group 1: Event Overview - The summit is organized by the Shanghai Biopharmaceutical Technology Industry Promotion Center, with support from major companies like Siemens Healthineers and Boston Scientific [12]. - It will feature discussions on cardiovascular, oncology, and neurodegenerative diseases, showcasing global clinical technologies and innovations [12]. - The event aims to create a dedicated communication platform for clinical innovators, enhancing collaboration and resource sharing [12]. Group 2: Expert Participation - The summit will host renowned experts, including Vivek Y. Reddy from Mount Sinai Hospital and Wang Jianan, a Chinese Academy of Sciences academician [13]. - Keynote speeches and roundtable discussions will cover topics such as next-generation therapies and the integration of innovative clinical pathways [13][14]. - The event will also address the role of policy in driving high-quality development in medical technology [14].

Group 1 - The "2025 Ophthalmic Medical Engineering Transformation Innovation Summit" was held in Hangzhou, focusing on the integration of medical and engineering innovations in the ophthalmic field [1][3] - The summit gathered industry experts and representatives to discuss the latest trends, challenges, and solutions in medical technology transformation, aiming to enhance the industrialization of medical technology achievements [1][2] - The Chinese ophthalmic medical device market has surpassed 200 billion yuan in 2024, with a high dependence on imported high-value consumables, reaching nearly 70% [2] Group 2 - The summit featured two core agendas: "Gathering Strengths and Coexistence" and "Chain Movement and Innovation," focusing on policy guidance and technological innovation in key areas such as ophthalmic technology development and cataract treatment [3] - Significant achievements in medical-engineering transformation were showcased, including the development of a new type of artificial lens and innovative non-invasive cataract treatment devices, supported by national key research projects [3][4] - The establishment of the "Medical-Engineering Integration Innovation Alliance" during the summit marks a new phase for clinical transformation projects in ophthalmology, supported by regulatory, industrial, and clinical collaboration [3][4] Group 3 - The summit emphasized the importance of collaboration between clinical medicine and engineering technology to overcome barriers and enhance the practical application of innovative ideas [4] - The company, Haohai Biological Technology, has developed a comprehensive transformation system covering raw material research, process innovation, clinical validation, and product transformation, aiming to enhance the quality of ophthalmic healthcare [4][5] - Haohai aims to accelerate the domestic production process of high-end technologies and provide comprehensive solutions for eye health, contributing to the "Healthy China 2030" initiative [5] Group 4 - The Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association aims to promote innovation and development in the medical device industry, facilitating collaboration among enterprises, research institutions, and medical organizations [6] - Haohai Biological Technology is a leading company in the ophthalmic field, focusing on the research, development, and production of medical devices and pharmaceuticals using biomedicine and genetic engineering technologies [7] - The company has established a global presence and aims to enhance its competitive edge in the ophthalmic medical device market through innovation and integration of high-quality raw materials [7]

Core Insights - The Hainan Boao Lecheng International Medical Tourism Pilot Zone has achieved significant progress in its special drug and medical device policy, with 476 imported special drugs and devices as of April 30, 2025, including 175 drugs and 301 devices [1] Group 1: Policy Advantages - The Lecheng Pilot Zone has four core policy advantages: special drug and device policy, real-world research policy for drugs and devices, real-world research policy for medical insurance, and special operation policy for public hospitals [1] - The special drug and device policy allows the import and use of new drugs and devices that have not yet been approved in China, enabling patients to access the latest global medical innovations more quickly and conveniently [1] Group 2: Future Plans - The Lecheng Medical Supervision Bureau plans to focus on "medical" as the core and actively serve the introduction of special drugs and devices through a traceability platform, transitioning from passive approval to proactive service [2] - The zone aims to introduce a full range of special drugs and devices related to specific diseases and specialties, creating a comprehensive multidisciplinary center for disease management [2] - The plan includes expanding the entire industrial chain of special drugs and devices through real-world data research and medical-engineering transformation, positioning Lecheng as a new highland for drug and device research and development [2] Group 3: Regulatory Commitment - The special drug and device policy is regarded as Lecheng's "golden signboard," with a commitment to maintaining medical safety, ethical safety, and policy safety [3] - The Lecheng Medical Supervision Bureau will continue to support the application of special drugs and devices and real-world data research while strengthening regulation to ensure medical safety [3]

Group 1 - The signing of a comprehensive cooperation agreement between Zhengzhou Airport and Shenzhen Mindray Biomedical Electronics marks a significant achievement in attracting investment in the biomedicine sector [3][9] - Mindray Medical is a global leader in medical devices, holding a crucial position in life information and support, in vitro diagnostics, and medical imaging [3][5] - Zhengzhou Airport aims to establish the Central Plains Medical Science City, focusing on integrating traditional Chinese and Western medicine, and has attracted numerous high-quality enterprises [5][9] Group 2 - The cooperation will involve creating an innovative medical engineering transformation platform, exploring the establishment of a national high-performance medical device sub-center, and planning a Mindray medical equipment storage center [5][9] - Mindray Medical expresses confidence in investing in Henan due to its strong industrial foundation, large market size, and promising development prospects [7][9] - The collaboration is expected to enhance regional medical service levels and technological innovation capabilities, benefiting both parties through mutual cooperation [9]